During the last session, Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)’s traded shares were 1.48 million, with the beta value of the company hitting 0.71. At the end of the trading day, the stock’s price was $0.26, reflecting an intraday gain of 3.08% or $0.01. The 52-week high for the SONN share is $2.07, that puts it down -696.15 from that peak though still a striking 7.69% gain since the share price plummeted to a 52-week low of $0.24. The company’s market capitalization is $15.96M, and the average intraday trading volume over the past 10 days was 0.83 million shares, and the average trade volume was 7.23 million shares over the past three months.
Sonnet BioTherapeutics Holdings Inc. (SONN) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. SONN has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.19.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) trade information
Sonnet BioTherapeutics Holdings Inc. (SONN) registered a 3.08% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.08% in intraday trading to $0.26 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -13.03%, and it has moved by -38.93% in 30 days. Based on these gigs, the overall price performance for the year is -82.35%. The short interest in Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) is 0.83 million shares and it means that shorts have 0.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.25, which implies an increase of 88.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $2.50 respectively. As a result, SONN is trading at a discount of -861.54% off the target high and -669.23% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 54.30%. While earnings are projected to return 85.40% in 2022.
Sonnet BioTherapeutics Holdings Inc. is due to release its next quarterly earnings between February 14 and February 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)’s Major holders
Sonnet BioTherapeutics Holdings Inc. insiders own 2.63% of total outstanding shares while institutional holders control 4.65%, with the float percentage being 4.78%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 20 institutions own stock in it. As of Sep 29, 2021, the company held over 1.78 million shares (or 2.95% of all shares), a total value of $1.08 million in shares.
The next largest institutional holding, with 0.5 million shares, is of Geode Capital Management, LLC’s that is approximately 0.82% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $0.3 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sonnet BioTherapeutics Holdings Inc. (SONN) shares are Vanguard Total Stock Market Index Fund and Fidelity NASDAQ Composite Index ETF. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.62 million shares. This amounts to just over 2.69 percent of the company’s overall shares, with a $0.98 million market value. The same data shows that the other fund manager holds slightly less at 0.45 million, or about 0.75% of the stock, which is worth about $0.29 million.